Deranged energy metabolism contributes to the pathophysiology of heart failure (HF). Recent studies showed diminished free fatty acid (FFA) oxidation in experimental HF models with a shift towards oxidation of ketone bodies. However, conflicting clinical data on FFA metabolism and limited knowledge on ketone body metabolism in human HF mandate additional metabolic profiling studies. We, therefore, investigated cardiac uptake of FFAs and ketone bodies (β-hydroxybutyrate and acetoacetate) in patients with HF with reduced ejection fraction (HFrEF) or with aortic stenosis (AS)-induced left ventricular hypertrophy. We hypothesized that FFA oxidation is impaired in HFrEF and in AS and results in decreased concentrations of free carnitine, the necessary carrier for mitochondrial entry of activated FFAs, and in accumulation of metabolic intermediates.
T
he prevalence of heart failure (HF) is ≈2% in the western world, and it is still associated with high morbidity and mortality rates despite pharmacological and nonpharmacological treatment. 1 Current guidelines have proposed more stringent diagnostic criteria for HF dividing it into 3 major types: HF with reduced ejection fraction (EF <40%, HFrEF), HF with mid-range ejection fraction (EF=40%-50%), and HF with preserved ejection fraction (EF >50%, HFpEF). 1 Current medical treatment of HFrEF consists of inhibition of neurohormonal and reninangiotensin-aldosterone signaling, and a subgroup of refractory patients may receive cardiac resynchronization therapy or a left ventricular (LV) assist device. In contrast, there are no specific evidence-based pharmacological or other treatments for patients with HFpEF.
A growing body of evidence suggests that development of HF is associated with abnormalities in cardiac energy metabolism. The failing heart shows an energy deficit and contains less ATP, as compared to a normal healthy heart, probably because of altered energy substrate availability and impaired mitochondrial oxidative capacity. 2, 3 In the healthy adult heart, the majority of ATP is produced by mitochondrial oxidation of fatty acids, and the remaining ATP mainly by oxidation of glucose. Other possible energy substrates include lactate, which can become an important source of ATP during exercise, ketone bodies, and amino acids (mainly branched-chain amino acids). Free fatty acids (FFAs) provide the highest energy (ATP) yield per molecule. After uptake into myocardial cells, FFAs are activated by conversion into acylcoenzyme A (CoA) esters. Long chain fatty acyl-CoAs require carnitine transport into the mitochondria for beta-oxidation, whereas medium-chain fatty acyl-CoAs can enter the mitochondria without carnitine transport. 4 Free carnitine and its acyl derivatives thus play a key role in beta-oxidation, 5 and an increase in plasma acyl-carnitines suggests ineffective beta-oxidation. 6 Myocardial uptake and oxidation of FFAs is generally considered diminished in HFrEF, 7, 8 although some studies showed unchanged or increased uptake of FFAs. 9, 10 In contrast, glucose uptake was shown to be increased in HFrEF. A switch from FFAs to glucose could theoretically be beneficial in case of ischemia because glucose oxidation generates more ATP per oxygen. The increased uptake of glucose may, however, be associated with an increase in energetically less efficient glycolysis (2 ATP/ molecule) rather than glucose oxidation (30-32 ATP/molecule). 8, 11 Recently, an animal study and a human study in end-stage HF showed a shift from FFA utilization towards oxidation of ketone bodies in HFrEF. 12, 13 Amino acids, especially branched-chain amino acids (BCAAs; leucine, isoleucine and valine), can also be oxidized in the heart, and their catabolism is impaired in murine and human cardiomyopathy. 14 The inhibition of BCAA metabolism in mice leads to impaired cardiac contractile function 14 and cardiac hypertrophy 15 in HF models, but data in HFrEF patients are lacking. HFpEF is strongly associated with metabolic syndrome and hypertrophic remodeling, but limited data are available on the direct measurement of myocardial uptake of FFAs and glucose in patients with HFpEF and no data on ketone body and BCAA metabolism. In 1 study in male patients with type 2 diabetes mellitus and without coronary artery disease, increased FFA uptake and oxidation was observed, whereas myocardial glucose uptake was decreased. 16 To better understand the energy metabolic adaptations associated with functional and structural remodeling, we measured cardiac uptake of FFAs, lactate, glucose, ketone bodies, and 7 amino acids (leucine, isoleucine, valine, glutamine, serine, glycine, and alanine) in patients with HFrEF or with severe aortic stenosis (AS)-induced LV hypertrophy. We hypothesized that (1) FFA oxidation is impaired in HFrEF and in AS, resulting in decreased concentrations of free carnitine, the necessary carrier for mitochondrial entry of activated FFAs, and in accumulation of metabolic intermediates, and (2) that ketone bodies and BCAAs could serve as alternative fuel sources in the failing heart.
METHODS
The data, analytic methods, and study materials will be made available to other researchers on request for purposes of reproducing the results or replicating the procedure.
WHAT IS NEW?
• We have directly measured increased myocardial uptake of ketone bodies in patients with heart failure with reduced ejection fraction or with aortic stenosis-induced myocardial hypertrophy. The uptake of free fatty acids was also increased in patients with aortic stenosis.
• The lack of myocardial release of acyl-carnitine species or change in free carnitine uptake suggests no impairment of free fatty acid oxidation.
WHAT ARE THE CLINICAL IMPLICATIONS?
• There are no specific evidence-based pharmacological or other treatments for patients with heart failure with preserved ejection fraction or for a subgroup of refractory patients with heart failure with reduced ejection fraction.
• Our patients with aortic stenosis showed characteristics of heart failure with preserved ejection fraction and myocardial uptake of ketone bodies, and free fatty acids may generally be increased in patients with heart failure with preserved ejection fraction.
• Pharmaceutical or dietary alteration of ketone body or free fatty acid metabolism could be a novel strategy for the treatment of heart failure also in patients with heart failure with preserved ejection fraction.
Study Population
The HFrEF group (n=15) consisted of patients undergoing implantation of a cardiac resynchronization device. In the LV hypertrophic remodeling group, patients with moderately severe AS (mean aortic valve area <0.8 cm 2 , n=15) and normal EF were included. Control patients (n=15) had a morphologically normal heart and underwent a radiofrequency catheter ablation procedure for atrial fibrillation (n=9), atrial flutter (n=4), or both (n=2). All patients were clinically stable for at least 1 month before completing the study protocol. A cardiac evaluation, including disease history, physical exam, ECG, and echocardiogram, was performed on admission. The study protocol was approved by the Institutional Review Board of University Hospitals Leuven and conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. All study participants provided written informed consent.
Collecting and Analyzing Blood Samples
After overnight fasting, arterial and coronary sinus (CS) blood samples were simultaneously collected from all patients during the procedures mentioned above. Lithium heparin blood was immediately deproteinized for the measurement of lactate, pyruvate, β-hydroxybutyrate, and acetoacetate using perchloric acid and stored at −20°C until measurement. A second lithium heparin tube without gel was collected for the other parameters. Lactate, pyruvate, β-hydroxybutyrate, and acetoacetate were measured enzymatically on a Cary 300 Bio UV-Visible Spectrophotometer from Agilent (Santa Clara, CA). Glucose was measured on a Roche Cobas 8000 e701 analyzer. FFAs were measured using the nonesterified fatty acids kit from Diagnostic Systems (Holzheim, Germany). Amino acids were measured with liquid chromatographymass spectrometry using the AccQ•Tag Ultra Derivitization Kit from Waters (Milford, MA), and free carnitine and acylcarnitines were measured with liquid chromatography-mass spectrometry using an in-house method. The arterial-CS (A-CS) concentration difference was subsequently calculated by subtracting CS concentrations from arterial concentrations in individual patients. A positive result indicates net uptake by the heart, whereas a negative result indicates net secretion. To calculate theoretical ATP production, an expected yield of ATP/molecule for complete mitochondrial oxidation was used for glucose (32) , lactate (15), β-hydroxybutyrate (22.5), acetoacetate (20) and FFAs (115)
Statistics
Continuous variables are presented as mean±SD or SE (SEM) as indicated, and discrete variables are presented as frequencies and percentages. Statistical calculations were performed using Prism 7 for Windows from GraphPad and Analyse-It for Microsoft Excel. The threshold for significance was set at P<0.05. Discrete variables were compared between groups using the Pearson χ 2 test. Results of continuous baseline characteristics (age, body mass index, EF), energy substrates, free carnitine, acyl-carnitines, and amino acids, including the gradients, were compared between the 3 groups using 1-way ANOVA and, if significant, a post hoc analysis was performed using Tukey multiple comparisons test. The possible impact of age as a covariate was examined using ANCOVA. The results of NT-proBNP (N-terminal pro-B-type natriuretic peptide) were compared using a nonparametric Kruskal-Wallis test and, if significant, a post hoc analysis was performed using Dunn multiple comparisons test. Correlations were studied using Spearman correlation test. Table 1 shows baseline characteristics of the 3 groups of patients. Patients with AS were significantly older and predominantly female (73%). Body mass index was comparable. Only few patients were treated with oral antidiabetics in the 3 groups, and no patient received insulin. The oral antidiabetic agents were metformin, gliclazide, or gliquidon, and no patients received an SGLT-2 (sodium-glucose transporter-2) inhibitor. Control and AS patients had normal LV EF, whereas patients with HFrEF had a significantly lower EF. Ten patients (67%) in the HFrEF group had ischemic cardiomyopathy, whereas only 6 patients (40%) in the AS group and 4 out of 7 patients (57%) in the control group had significant coronary stenoses. No coronary angiography was performed in 8 control patients as it was clinically not indicated. Table 2 shows hemodynamic and echocardiographic parameters of patients with AS. The patients had a slightly increased pulmonary capillary wedge pressure and a moderate postcapillary pulmonary hypertension. The degree of AS was severe based on mean transaortic pressure gradient and valve surface, and the patients had a slight ventricular hypertrophy. Figure 1 shows arterial, CS concentrations, and concentration gradients of glucose, FFAs, lactate, and ketone bodies. In both HFrEF and AS groups, NT-proBNP concentrations were significantly higher in both arterial and CS samples compared with control, and A-CS gradients showed, as expected, a significantly increased myocardial release of NT-proBNP in AS (−197 ng/L median; −409 to −114 ng/L interquartile range) and HFrEF (−287 ng/L median; −729 to −153 ng/L interquartile range) compared with control patients (−31 ng/L median; −14 to −84 ng/L interquartile range; P<0.01 versus AS or HFrEF). In the AS group, but not in HFrEF, FFA concentrations were significantly higher in arterial samples, and A-CS gradients were also significantly higher as compared to control patients, suggesting increased FFA uptake in AS patients. This statistical effect was independent of age.
RESULTS
The arterial concentrations of β-hydroxybutyrate and acetoacetate were slightly but not significantly higher in both HFrEF and AS groups as compared to controls. The A-CS gradients of both ketone bodies were, however, markedly increased in HFrEF patients. In the AS group, A-CS gradient of β-hydroxybutyrate was significantly higher as compared to control patients, and there was also a trend towards a higher A-CS gradient of acetoacetate, but it did not reach statistical significance. Arterial, CS concentrations, and A-CS gradients of glucose and lactate were comparable between the groups. Figure 2 shows the relative extraction (A-CS gradient divided by arterial concentration) of these energy sources. The relative extraction of β-hydroxybutyrate was significantly higher in both HFrEF and AS patients as compared to controls but that of acetoacetate and FFAs did not reach statistical significance. No difference was observed in the A-CS gradients of the 7 amino acids with somewhat higher gradients of leucine and isoleucine in the AS group as compared to control patients (Figure 3 ). The concentration of free carnitine was not different between the patient groups in all samples (Table 3) . Although the concentration of multiple acyl-carnitine species was significantly higher in the arterial and CS samples of HFrEF and AS patients as compared to the control group, the A-CS gradients of most acyl-carnitines were comparable between the groups ( Table 3) . The correlations between A-CS gradients of NT-proBNP and the cumulative A-CS gradients of β-hydroxybutyrate and acetoacetate are shown in Figure 4 . A significant positive correlation was observed when all the patient groups were investigated together. The correlations in the separate groups alone, however, did not reach statistical significance (data not shown). Figure 5 shows the theoretical contribution of glucose, FFAs, lactate, β-hydroxybutyrate, and acetoacetate to the myocardial ATP production under the assumption that all energy sources are fully oxidized in the mitochondria. The contribution of the 7 investigated amino acids was negligible because of the low A-CS gradients compared with the other energy sources. The energetic value of the energy sources expressed as mmol ATP per liter was 30% higher in HFrEF and 120% higher in AS compared with controls. The relative contribution of FFAs and glucose decreased in HFrEF, whereas 
Figure 1. Myocardial uptake of energy substrates in heart failure with reduced ejection fraction (HFrEF) and aortic stenosis (AS).
Arterial concentrations (A; red bars), coronary sinus (CS) concentrations (blue bars), and A-CS concentration gradients (gray bars) of free fatty acids, glucose, lactate, β-hydroxybutyrate, and acetoacetate in patients with HFrEF (n=15) or AS (n=15) and in control subjects (n=15). A positive A-CS gradient indicates net uptake by the heart, whereas a negative result indicates net secretion. *P<0.05 and **P<0.01 vs controls. Data are mean±SEM.
that of ketone bodies increased. The cumulative relative contribution of β-hydroxybutyrate and acetoacetate to the ATP production increased from 6.8% in controls to 24% in the HFrEF group. Similarly, a lower relative contribution of glucose and a higher contribution of ketone bodies was observed in the AS group as compared to the controls.
DISCUSSION
In our study, we investigated the cardiac uptake of FFAs, lactate, glucose, ketone bodies, and 7 amino acids (leucine, isoleucine, valine, glutamine, serine, glycine, and alanine) in patients with HFrEF or with AS induced LV hypertrophy. Patients without structural heart disease who underwent a radiofrequency catheter ablation procedure served as control. Our results show that cardiac uptake of ketone bodies was markedly (4-5-fold) increased in both HFrEF and AS compared with control patients and that FFA uptake was significantly higher in AS compared with control patients. The finding of increased ketone body uptake in HFrEF supports the results of recent animal and human studies 12, 13 showing increased oxidation of ketone bodies in HF. Another recent study also showed increased arterial concentrations and myocardial uptake of ketone bodies in diabetic patients as compared to nondiabetic controls. 17 In our study, arterial concentrations of ketone bodies were somewhat higher in both HFrEF and AS groups as compared to control patients. The higher arterial concentrations, however, cannot sufficiently explain the increased myocardial uptake as also the relative extraction of β-hydroxybutyrate was significantly higher in both HFrEF and AS patients (Figure 3 ). Whether this increased utilization of ketone bodies is adaptive or maladaptive is currently not clear, but some data in the literature Arterial-coronary sinus concentration gradients of free fatty acids, glucose, lactate, β-hydroxybutyrate, and acetoacetate were divided by their arterial concentrations in patients with HFrEF (n=15) or AS (n=15) and in control subjects (n=15). A positive extraction indicates net uptake by the heart, whereas a negative result indicates net secretion. *P<0.05 vs controls. Data are mean±SEM.
Figure 3. Myocardial uptake of amino acids in heart failure with reduced ejection fraction (HFrEF) and aortic stenosis (AS).
Arterial concentrations (A; red bars), coronary sinus (CS) concentrations (blue bars), and A-CS concentration gradients (gray bars) of leucine, isoleucine, valine, glutamine, glycine, serine, and alanine in patients with HFrEF (n=15) or AS (n=15) and in control subjects (n=15). A positive A-CS gradient indicates net uptake by the heart, whereas a negative result indicates net secretion. *P<0.01 vs controls. Data are mean±SEM. support a potential beneficial effect of ketone body metabolism in HFrEF. Empagliflozin, an SGLT-2 inhibitor, was shown to reduce cardiovascular mortality and hospitalizations for HF. 18 One of the possible mechanisms is that empagliflozin increases the plasma concentration of ketone bodies, which may improve efficiency of myocardial energy metabolism. 19 Another study showed that infusion of β-hydroxybutyrate increased myocardial blood flow by vasodilation. 20 Further interventional studies are, however, necessary to directly address the role of increased ketone body uptake in HFrEF. The A-CS gradients were also increased in AS compared with control patients to a similar extent as observed in the HFrEF group. To our knowledge, ours is the first study to directly measure myocardial ketone body uptake in patients with AS. These patients also showed characteristics of HfpEF, including higher pulmonary capillary wedge pressure, and increased release of NT-proBNP. It is tempting to speculate that myocardial uptake of ketone bodies is generally increased in HFpEF patients, which needs to be investigated in future studies. The increased uptake of ketone bodies in patients with HFrEF and AS would also suggest that increasing ketone body production might be a potential future strategy for the treatment of HF.
We measured a significant increase in myocardial FFA uptake in AS, but not in HFrEF, patients as compared to controls, whereas glucose uptake was unchanged in both groups. It is generally accepted that FFA metabolism is impaired in HFrEF, especially in end-stage HF 11, 13 and 1 study even showed cardiac accumulation of toxic intermediates, diacylglycerol, and ceramides. 21 In less severe forms of human HFrEF, however, the results are conflicting. Studies with cardiac positron emission tomography 7 or direct measurements of A-CS gradients of radiolabeled tracers 8 showed decreased myocardial uptake and oxidation of FFAs and increased utilization of glucose in patients with dilated cardiomyopathy. Other positron emission tomography studies showed, however, increased myocardial FFA uptake in HFrEF 22 and a reduction of FFA uptake after treatment with carvedilol and improvement of EF in dilated cardiomyopathy. 23 Two other invasive studies showed unchanged 9 or increased 10 myocardial uptake of FFAs and impaired glucose uptake in HFrEF. These discrepancies are likely attributable to different patient populations (ischemic or nonischemic cardiomyopathy), severity of HF, and differences of experimental methods. We measured significantly higher A-CS gradients of FFAs in patients with AS compared with controls. It cannot be ruled out that the increased FFA uptake in AS is because of the higher arterial FFA concentrations as the relative extraction was not significantly different between the groups (Figure 2 ) with or without correction for age. The observed differences in FFA arterial concentrations and uptake between HFrEF and AS compared with control patients emphasize the need of a targeted approach as the underlying cause and metabolic derangement in individual patients determine whether modulation of cardiac FFA metabolism is beneficial or could be detrimental. Inhibition of FFA oxidation in HF may, for example, be beneficial in case of lower oxygen supply because FFA oxidation generates less ATP per oxygen (P/O ratio) as compared to glucose or ketone bodies. 24 There is only limited information on glucose or FFA uptake and oxidation in HFpEF or AS in humans. One study with cardiac positron emission tomography showed increased cardiac uptake and oxidation of FFAs in obese and insulin resistant women. 25 In AS, a predominant reliance on FFA as myocardial energy source was shown, 26 but a control group without AS was not included in that study. It is also unknown whether increased FFA uptake is beneficial or not in HFpEF. Transgenic mice exhibiting increased FFA uptake develop cardiac hypertrophy and diastolic dysfunction 27 but other transgenic models with impaired FFA oxidation also show an enhanced response to pressure overload-induced HF. 28 Lower myocardial free carnitine concentrations 29 and elevated plasma levels of carnitine and some acyl-carnitines have been reported in patients with HF. In recent studies, plasma carnitine and acyl-carnitine levels correlated significantly with impaired LV systolic function, 30 New York Heart Association functional class, 31 and adverse clinical outcome. 32 In our study, the plasma concentration of free carnitine was comparable between the patient groups. Although arterial and CS concentration of many of the investigated acyl-carnitine species was significantly higher in HFrEF and AS groups as compared to the controls, A-CS gradients were not different. Our results suggest that higher plasma levels of acyl-carnitine species in HF patients are not the direct result from a higher myocardial release but rather reflect a broader metabolic dysregulation. In addition, the lack of myocardial release of acyl-carnitine species or change in free carnitine uptake in our patients suggests no impairment of FFA oxidation. According to the literature, BCAA catabolism is impaired in HF and BCAAs may cause cardiac hypertrophy and decreased myocardial contractility, 14,15 but we did not find significantly different A-CS gradients of BCAAs and the 4 other investigated amino acids in our patient groups.
We recognize the limitations of our study. The sample size is relatively small and includes patients with both ischemic and nonischemic cardiomyopathy. Myocardial blood flow and oxidation of the different substrates were also not directly measured. The contribution of the measured energy sources to myocardial ATP production ( Figure 5 ) is only a theoretical assumption as uptake from the blood does not necessarily mean complete mitochondrial oxidation in myocardial cells. Direct measurement of oxidation of ketone bodies in HF has not been performed yet and requires further investigation. As patients with AS were significantly older as compared to control patients, we cannot exclude an effect of higher age on the observed differences in the myocardial uptake of energy sources. There was, however, no significant correlation between A-CS (arterial-coronary sinus) gradients of NT-proBNP (horizontal axis) were positively correlated with cumulative A-CS gradients of β-hydroxybutyrate and acetoacetate (vertical axis) in heart failure with reduced ejection fraction (HFrEF; blue circles), AS (red circles), and control patients (green circles). Figure 5 . Contribution of energy sources to the myocardial ATP production. Theoretical absolute (A) and relative (B) contribution of glucose (gray), free fatty acids (yellow), lactate (black), acetoacetate (blue), and β-hydroxybutyrate (red) to the myocardial ATP production. To calculate theoretical ATP production an expected yield of ATP/molecule for complete mitochondrial oxidization was used (see Methods). AS indicates aortic stenosis; and HFrEF, heart failure with reduced ejection fraction.
age and A-CS gradients of FFAs or ketone bodies when the 3 patient groups were investigated together (data not shown). A statistical analysis with ANCOVA showed, furthermore, no significant effect of age as an independent covariate on the myocardial uptake of all the energy substrates. The statistical differences and conclusions remained the same even after correction for age. In contrast, the strength of the study is the comparative and comprehensive analysis of a broad range of myocardial energy sources in both HFrEF and AS. The results in patients with AS may provide new insights into the metabolism of myocardial hypertrophy and HFpEF, which has not yet been intensively studied in humans.
In conclusion, our results show significantly increased cardiac uptake of ketone bodies in patients with stable HFrEF and AS and increased uptake of FFAs in AS compared with control patients. The lack of myocardial release of acyl-carnitine species and the unchanged free carnitine uptake suggest no significant impairment of FFA oxidation in our patients. Further studies are necessary to investigate the possible adaptive or maladaptive role of these metabolic changes and whether increasing ketone body production could be a novel strategy for the treatment of HF.
